Join Our Crew

Scientist, Cell and Gene Therapy

Philadelphia, PA

About Cabaletta Bio

Cabaletta Bio (NASDAQ: CABA) is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-expressing B cells while sparing normal antibody-expressing B cells, which are essential for human health. Cabaletta’s Approach for selective B cell Ablation platform, called our CABA™ platform, has applicability across more than two dozen B cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. CAAR T technology is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop CAAR T technology to treat B cell-mediated autoimmune diseases.

The Company’s lead product candidate, DSG3-CAART, received IND clearance from the FDA in September 2019, and initial safety data in clinical trials has been reported. DSG3-CAART is designed to be a potential treatment for patients with mucosal pemphigus vulgaris (mPV), which is a rare autoimmune blistering disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. Cabaletta Bio is also pursuing additional pipeline candidates for other B cell mediated disorders including MuSK Myasthenia Gravis (MG) with an IND planned for 2H 2021, mucocutaneous PV, PLA2R positive membranous nephropathy (PMN), and Factor VIII inhibitors.

Uniquely Differentiated. Rapid. Elegant.

At Cabaletta, we are driven by the shared mission of developing a new type of therapy, where patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that success in the Cabaletta mission lies in the hands of individuals across every aspect of the company. To nurture this, we make an active commitment to the well-being and continuous growth of each person who joins our team. In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew

About the Position

The Scientist reports to the Senior Director of Gene Transfer Technologies and is involved in establishing and optimizing processes for genetic engineering and transitioning them into the process development team. The incumbent should have prior experience in viral and non-viral gene transfer technologies as well as prior exposure to cell manufacturing processes. This position is in close contact with the cell manufacturing group and will frequently perform work using cell manufacturing equipment. This role will be able to independently perform various analytical experiments related to quantifying gene engineering rates and evaluating the function of engineered target cells in cell based assays.  Compliance with quality principles and fastidious data documentation is essential.  Capabilities for productive experimental design including appropriate controls, as well as timely and informative data analysis with a personal culture of open discussion of findings with colleagues is critical.  The candidate must be a self-starter with proactive communication skills and be able to work effectively in the context of a matrixed organization.

Responsibilities Include

  • Design and conduct lentiviral process optimization experiments
  • Establish in house protocols for efficient gene engineering and perform technology transfer to the internal Process Development team.
  • Perform cell based bioassays to evaluate function and potency of gene engineered cells
  • Be innovative and demonstrate initiative in adopting and learning new techniques
  • At all times, adhere to data integrity best practices in both the conduct and recording of experiments in the ELN

Required Qualifications

  • MS in a related scientific discipline with 3 - 5 years of experience in academia or industry, or PhD in Virology, Molecular Biology, or related discipline with 1 + years of experience.
  • Proficiency in aseptic handling of mammalian cells
  • Experience with production, titration and use of lentivirus for the manufacturing of engineered primary human cells
  • Must be highly organized and able to work independently, must be able to clearly communicate in writing, must have a desire to be part of a growing organization that uses cutting-edge science.
  • Prior work experience in matrix managed organizations and ability to work in a team-oriented culture.

Preferred Qualifications

  • Analytic experience (flow cytometry, PCR, ELISA, bioassays)
  • Experience with non-viral gene transfer technologies (e.g. electroporation) for manufacturing of engineered human cells
  • Experience managing external CROs and academic collaborators as well as performing tech transfers to external organizations

How to Apply

Please email careers@cabalettabio.com directly to submit an application.

Please include your CV along with the title of the position you are applying for.

Benefits

Our most important asset is our people and we offer competitive benefits including health and retirement, PTO, and stock option plans.

Equal Opportunity Employer

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.